 |
市場調查報告書
商品編碼
1378706
譫妄管理的興奮市場：依藥物類型、給藥途徑、配銷通路和地區分類Agitation in Delirium Management Market, By Drug Type, By Route of Administration, By Distribution Channel, By Geography |
||||||
價格
簡介目錄
到 2023 年，譫妄管理中的躁動的全球市場規模預計為 2.372 億美元，預計在預測期內（2023-2030 年）年複合成長率為 4.6%。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年 | 2022年 | 2023年市場規模 | 2.372 億美元 |
| 實績資料 | 2018-2021 | 預測期 | 2023-2030 |
| 預測期年複合成長率 | 4.60% | 2030年市場規模預測 | 3.249 億美元 |
譫妄通常與多種疾病有關，需要多種藥物治療。早期發現和及時治療可以降低患者發病率、住院時間、醫療費用和死亡率。英國註冊的為老年人提供護理和臨終關懷的機構瑪麗居里在其網站上表示，許多患者在生命的最後幾天出現譫妄，導致煩躁不安，據說會導致懶惰。這有時被稱為末期不安或末期激動。第一代抗精神病藥物是譫妄控制患者躁動的第一線治療藥物，其次是第二代抗精神病藥物和苯二氮平類藥物。譫妄是心理能力的顯著改變。你的思緒變得混亂，你失去了對周遭環境的認知。譫妄通常會在數小時至數天內迅速發展。譫妄通常是由一種或多種因素引起的。促成因素包括嚴重或長期疾病以及身體失衡，例如低鈉。它也可能是由某些藥物、感染疾病、手術、酒精或藥物使用或戒斷症狀引起的。
市場動態
預計主要市場參與企業活性化的研發活動將在預測期內推動全球譫妄管理激動市場的成長。例如，2023年9月11日，製藥公司工業株式會社宣布開始中樞神經系統（CNS）抑制劑/催眠藥物雷美替胺（Rozerem）的臨床試驗。 Ramelteon 是一種中樞神經系統抑制劑和催眠藥，可給藥薄膜衣片或包衣片。
本研究的主要特點
- 該報告深入分析了全球譫妄管理市場的風潮，並提供了以2022年為基準年的預測期（2023-2030年）的市場規模和年複合成長率(CAGR)。
- 它還揭示了各個細分市場的潛在商機，並為該市場說明了一系列有吸引力的投資提案。
- 它還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要考察。
- 它根據公司亮點、產品系列、主要亮點、績效和策略等參數，介紹了全球譫妄管理市場興奮的主要企業。
- 該報告的見解使行銷人員和公司負責人能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的資訊。
- 令人興奮的全球譫妄管理市場報告迎合了該行業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
- 透過用於分析全球譫妄管理市場興奮的各種策略矩陣，將有助於相關人員做出決策。
目錄
第1章 調查目的和假設
- 這項研究的目的
- 假設
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
第3章 市場動態、法規及趨勢分析
- 市場動態
- 促進因素
- 抑制因素
- 市場機會
- 影響分析
- 最近的產品核准/發布
- 合併、收購和合作
- 法規場景
- 價格分析
- 主要進展
- PEST分析
- 波特的分析
第4章 全球譫妄管理市場活躍－新型冠狀病毒感染疾病（COVID-19）影響分析
- 經濟影響
- 新型冠狀病毒感染疾病（COVID-19）的流行病學
- 對需求和供給的影響
第5章 2018-2030 年全球譫妄管理興奮市場（依藥物類型）
- 第一代抗精神病藥
- 第二代抗精神病藥
- 苯二氮平類
第6章 譫妄管理的全球興奮市場（按給藥途徑），2018-2030 年
- 口服
- 肌肉注射
- 其他
第7章 2018-2030 年全球譫妄管理市場的興奮程度（依配銷通路）
- 醫院藥房
- 零售藥房
- 網路藥房
第8章 2018-2030 年全球譫妄管理市場的興奮程度（按地區）
- 北美洲
- 美國
- 加拿大
- 歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太地區
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
- 中東
- GCC
- 以色列
- 其他中東地區
- 非洲
- 北非
- 中部非洲
- 南非
第9章 競爭形勢
- 公司簡介
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Glenmark Pharmaceuticals Limited
- Mylan NV
- Fresenius Kabi AG
- Novartis AG
- Akorn Incorporated
- Zydus Cadila
- Pfizer, Inc.
- BioXcel Therapeutics, Inc.
- Takeda Pharmaceutical Company Limited
- 分析師觀點
第10章 章
- 參考
- 調查方法
簡介目錄
Product Code: CMI4430
Global agitation in delirium management market is estimated to be valued at US$ 237.2 Mn in 2023, and is expected to exhibit a CAGR of 4.6% during the forecast period (2023-2030).
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2022 | Market Size in 2023: | US$ 237.2 Mn |
| Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
| Forecast Period 2023 to 2030 CAGR: | 4.60% | 2030 Value Projection: | US$ 324.9 Mn |
Delirium is commonly associated with myriad conditions and requires a variety of medications. Early recognition and on-time treatment can help reduce morbidity, length of hospital stay, health care costs, and mortality in patients. According to Marie Curie, a registered organization in the U.K. that provides nursing and hospice care to elderly patients, they have mentioned on their website that many patients develop delirium in the last few days of their lives, which can cause agitation or restlessness. This is sometimes called terminal restlessness or terminal agitation. First-generation antipsychotics are the first choice of treatment for agitation in delirium management patients, followed by second-generation antipsychotics and benzodiazepines. Delirium is a serious change in mental abilities. It results in confused thinking and a lack of awareness of someone's surroundings. The disorder usually comes on fast, within hours or a few days. Delirium can often be traced to one or more factors. Factors may include a severe or long illness or an imbalance in the body, such as low sodium. The disorder may also be caused by certain medicines, infection, surgery, or alcohol or drug use or withdrawal.
Market Dynamics
Increasing research and development activities by key market players is expected to drive the global agitation in delirium management market growth over the forecast period. For instance, on September 11, 2023, Takeda Pharmaceutical Company Limited, a pharmaceutical company, announced that they had started a clinical trial for Ramelteon (Rozerem), a central nervous system (CNS) depressant and hypnotic. It is formulated as film-coated tablets and coated tablets for oral route of administration.
Key features of the study:
- This report provides an in-depth analysis of the global agitation in delirium management market and provides market size (US$ Mn) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global agitation in delirium management market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Mylan N.V., Fresenius Kabi AG, Novartis AG, Akorn Incorporated, Zydus Cadila, Pfizer, Inc., BioXcel Therapeutics, Inc., and Takeda Pharmaceutical Company Limited
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global agitation in delirium management market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global agitation in delirium management market
Detailed Segmentation:
- By Drug Type:
- First-generation Antipsychotics
- Second-generation Antipsychotics
- Benzodiazepines
- By Route of Administration:
- Oral
- Intramuscular
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
- Company Profiles
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Glenmark Pharmaceuticals Limited
- Mylan N.V.
- Fresenius Kabi AG
- Novartis AG
- Akorn Incorporated
- Zydus Cadila
- Pfizer, Inc.
- BioXcel Therapeutics, Inc.
- Takeda Pharmaceutical Company Limited
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Product Approvals/Launches
- Mergers, Acquisitions, and Collaborations
- Regulatory Scenario
- Pricing Analysis
- Key Developments
- PEST Analysis
- Porter's Analysis
4. Global Agitation in Delirium Management Market - COVID-19 Impact Analysis
- Economic Impact
- COVID-19 Epidemiology
- Impact on Supply and Demand
5. Global Agitation in Delirium Management Market, By Drug Type, 2018- 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- First-generation Antipsychotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Mn)
- Segment Trends
- Second-generation Antipsychotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
- Benzodiazepines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
6. Global Agitation in Delirium Management Market, By Route of Administration, 2018 - 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
- Intramuscular
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
7. Global Agitation in Delirium Management Market, By Distribution Channel, 2018 - 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
8. Global Agitation in Delirium Management Market, By Region, 2018 - 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Mn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Company Profiles
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Glenmark Pharmaceuticals Limited
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Mylan N.V.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Fresenius Kabi AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Novartis AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Akorn Incorporated
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Zydus Cadila
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Pfizer, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- BioXcel Therapeutics, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Analysts' Views
10. Section
- References
- Research Methodology
- About us and Sales Contact
